BPMC - Blueprint Medicines Corporation Stock Trading

Blueprint Medicines Corporation(NASDAQ: BPMC) stock trading, description, contact, officers and directors.

About Blueprint Medicines Corporation

Not available

Stock Information

Blueprint Medicines Corporation Company Name:

BPMC Stock Symbol:

NASDAQ Market:

BPMC - Blueprint Medicines Corporation Stock Trading

Get BPMC Alerts

News, Short Squeeze, Breakout and More Instantly...

BPMC - Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors

Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors -- First highly effective treatment option approved in Europe for PDGFRA D842...
BPMC - Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT(TM) (avapritinib) in Patients with Advanced Systemic Mastocytosis

Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Patients with Advanced Systemic Mastocytosis -- 76% confirmed ORR in EXPLORER, with a median duration of response of 38.3 months -- -- 75% confirme...
BPMC - Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO(TM) (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Cancer

CAMBRIDGE, Mass. , Sept. 20, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced results from the ongoing ARROW clinical trial showing durable respo...